Filing Flows › Immucell (ICCC) › Gross margin
Immucell (ICCC) gross margin by quarter
Immucell's gross margin was 33.9% in Q2 2026 (second quarter 2026), -11.1 pts from Q1 2026. Over the last 5 quarters it ranged from 33.9% (Q2 2026) to 45.0% (Q1 2026).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | 33.9% | -11.1 pts | -9.8 pts |
| Q1 2026 | 45.0% | +1.2 pts | +3.4 pts |
| Q2 2025 | 43.7% | +2.1 pts | — |
| Q1 2025 | 41.6% | +5.0 pts | — |
| Q4 2024 | 36.5% | — | — |
Q2 2026 at a glance
Immucell, Q2 2026: revenue $7.2M (+12% year over year), operating margin 26.9%, net earnings $1.8M, operating cash flow $3.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Immucell's gross margin?
Immucell's gross margin was 33.9% in Q2 2026 (second quarter 2026), -11.1 pts from Q1 2026.
How has Immucell's gross margin changed?
Over the last 5 quarters it ranged from 33.9% (Q2 2026) to 45.0% (Q1 2026).